Dr. Singh brings a track record of leadership and innovation
from the FDA's Oncology Center of Excellence, with deep expertise
in precision medicine and clinical development
BETHESDA, Md., May 22, 2024
/PRNewswire/ -- Precision for Medicine, a global leader in
biomarker-driven clinical research and development, today
announced that Harpreet Singh,
MD, has joined the company as Chief Medical Officer. Dr. Singh was
previously Division Director of Oncology at the U.S. Food and Drug
Administration (FDA), and in her new role will be responsible for
medical strategy and oversight.
With insights gleaned from her years at the FDA, Dr. Singh is in
a unique position to help existing and future clients optimize
development and navigate a complex regulatory environment.
Motivated by a desire to accelerate breakthrough treatments in
oncology and rare disease, Dr. Singh brings to Precision a
multi-dimensional understanding of drug development along with deep
experience as a medical oncologist. Dr. Singh will also provide
medical and strategic support for business development activities
and continue her active public presence as a thought leader for
important issues facing the life sciences industry.
"The wealth of experience that Dr. Singh brings to Precision
from over a decade of experience at the FDA and National Cancer
Institute will be invaluable to our organization, our clients and,
ultimately, patients," said Sofia
Baig, President, Clinical Solutions, at Precision for
Medicine. "She is a proven leader in precision medicine, novel
trial design and innovative regulatory initiatives designed to
expedite clinical development. We are excited to add Dr. Singh's
unique skill set to our leadership team."
Dr. Singh joins Precision with a track record of leadership at
the FDA where she oversaw multiple oncology and rare disease
programs. Most recently, Dr. Singh was Director, Division of
Oncology 2, Office of Oncologic Diseases, a division that regulated
drugs and biologics for the treatment of thoracic and head and neck
malignancies, neurologic tumors, pediatric solid tumors and rare
tumors. While at the FDA, she spearheaded Project Pragmatica, a
program to streamline clinical trial procedures and enhance patient
centricity by integrating aspects of trials with real-world routine
clinical practice and pragmatic design elements. In addition, Dr.
Singh applied her large body of work in geriatrics as Associate
Director for Cancer in Older Adults and Special Populations at the
FDA Oncology Center of Excellence (OCE). She was previously a
Fellow at the National Cancer Institute.
"As a physician and scientist, I'm thrilled to be joining the
Precision team," said Dr. Singh. "The mission and vision of the
company fits perfectly with my experience and passion to bring
life-saving therapies to market faster."
About Precision for Medicine
Precision for Medicine is
the first biomarker-driven clinical research and development
services organization supporting life sciences companies in the use
of biomarkers essential to targeting patient treatments more
precisely and effectively. Precision applies a transformational
approach to clinical research that integrates clinical trial design
and execution with deep scientific knowledge, laboratory expertise,
data intelligence and advanced manufacturing solutions. This
convergence is driving faster clinical development and approval.
Precision for Medicine is part of Precision Medicine Group, with
3,500 people in 40 locations globally across North America, Europe and Asia-Pacific. For more information, visit
PrecisionForMedicine.com.
For more information contact:
GCI Health
PrecisionGCIHealth@gcihealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harpreet-singh-md-departs-the-fda-and-joins-precision-for-medicine-as-chief-medical-officer-302152014.html
SOURCE PRECISION FOR MEDICINE